News

The extension study enrolled 93 patients, of which 32 were treated with Fosrenol for up to six years. The study revealed that as patients continued with the therapy,

Amgen now expects to file new data with the FDA on extended dosing regimens for Aranesp in chronic kidney disease (CKD) by the end of 2005. In the

The researchers hope to find a way of genetically characterizing patients to predict responsiveness to treatment, and help physicians to determine the best treatment option for their patients.

Morphotek will apply its proprietary Human Morphodoma antibody technology to develop novel antibodies for use in the treatment of advanced melanoma, lung cancer and other solid malignancies that

The study of 58 patients found that RenaMed’s therapy increased survival rate by 72% at 28 days, a trend for improved survival sustained through 90 and 180 days.

Results from the trial of the compound have shown that it decreases urinary albumin excretion rate (UAER) and total cholesterol in patients with diabetic kidney disease when administered

The methylphenidate transdermal system (MTS) patch was developed by Noven Pharmaceuticals and is licensed to Shire. It combines the active ingredient of methylphenidate with Noven’s patented DOT Matrix

The trial compared the PrimeBoost therapy with lamivudine (marketed by GlaxoSmithKline as Epivir), which is approved for the treatment of hepatitis B. At 14 weeks, Oxxon’s PrimeBoost immunotherapy

According to the company, the rapid decline in plasma hepatitis C virus-RNA levels observed in patients taking VX-950, together with a viral kinetic analysis that projects the potential